Metabolite is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-30. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Colloquially, radioactive materials can be described as "hot," and non-radioactive materials can be described as "cold." There are instances in which cold iodide is administered to people in order to prevent the uptake of hot iodide by the thyroid gland. For example, blockage of thyroid iodine uptake with potassium iodide is used in nuclear medicine scintigraphy and therapy with some radioiodinated compounds that are not targeted to the thyroid, such as iobenguane (MIBG), which is used to image or treat neural tissue tumors, or iodinated fibrinogen, which is used in fibrinogen scans to investigate clotting. These compounds contain iodine, but not in the iodide form. However, since they may be ultimately metabolized or break down to radioactive iodide, it is common to administer non-radioactive potassium iodide to insure that metabolites of these radiopharmaceuticals is not sequestered by the thyroid gland and result in a concentrated radiation dose to that tissue. Potassium iodide has been distributed to populations exposed to nuclear fission accidents such as the Chernobyl disaster. The iodide solution SSKI, a saturated solution of potassium (K) iodide in water, has been used to block absorption of the radioiodine. Tablets containing potassium iodide are now also manufactured and stocked in central disaster sites by some governments for this purpose.
Spironolactone is an antimineralocorticoid (antagonist of the mineralocorticoid receptor) and potassium-sparing diuretic, which is mainly used to treat high blood pressure, edema, high aldosterone levels, and low potassium levels caused by other diuretics, among other uses. Spironolactone is an antiandrogen as a secondary and originally unintended action. It works as an antiandrogen mainly by acting as an androgen receptor antagonist. The medication is also a weak steroidogenesis inhibitor, and inhibits the enzymatic synthesis of androgens. However, this action is of low potency, and spironolactone has mixed and inconsistent effects on hormone levels. In any case, testosterone levels are usually unchanged by spironolactone. Studies in transgender women have found testosterone levels to be unaltered with spironolactone or to be decreased. Spironolactone is described as a relatively weak antiandrogen. It is widely used in the treatment of acne, excessive hair growth, and hyperandrogenism in women, who have much lower testosterone levels than men. Because of its antimineralocorticoid activity, spironolactone has antimineralocorticoid side effects and can cause high potassium levels. Hospitalization and/or death can potentially result from high potassium levels due to spironolactone, but the risk of high potassium levels in people taking spironolactone appears to be minimal in those without risk factors for it. As such, monitoring of potassium levels may not be necessary in most cases.
Geraniol 8-hydroxylase is a cytochrome P450 protein containing heme. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate (NADPH).
== Welfare implications == Beak trimming can cause acute stress, and possibly chronic pain following the trimming. A bird's ability to consume food is impaired following beak trimming because of the new beak shape and pain. Most studies report reduced body weights and feed intake following beak trimming; however, by sexual maturity or peak egg production, growth rates are usually normal. Weight losses were reduced in chicks that were beak trimmed by infrared compared with chicks trimmed by a hot-blade. Pain caused by beak trimming depends on the age it is performed, the method of trimming and the length of beak that is removed. Beak trimming in the poultry industry usually occurs without anaesthetic at 1-day of age or when the chicks are very young, but can occur at a later age if an outbreak of feather pecking occurs, and in some cases, birds may be beak trimmed on repeated occasions. Beak trimming is not permitted in the UK on meat chickens that are aged over 10 days.
Sources: en.wikipedia.org
== External links == "Opioid Receptors: μ". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. mu+Opioid+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human OPRM1 genome location and OPRM1 gene details page in the UCSC Genome Browser.
=== 1 April === A court in Kyiv ordered the house arrest of Metropolitan Pavlo (born Petro Lebid) of the Ukrainian Orthodox Church (Moscow Patriarchate) for allegedly supporting the Russian invasion of Ukraine. He was later taken under police custody on 14 July. Russia assumed the presidency of the UN Security Council for the month, a role in which Russia was able to maneuver meetings on Ukraine to portray the US and other Western countries as making false accusations against Russia.
Operation LabScam was a United States government investigation in the 1990s by a seven-member taskforce into laboratory billing fraud resulting in $800 million in fines. Fraudulent billing practices included labs billing Medicare and other government healthcare programs for medically unnecessary tests, upcoded tests, tests that were never conducted, and providing kickbacks to physicians. The following labs were implicated: Damon Clinical Laboratories, SmithKline Beecham Clinical Laboratories (SBCL), Corning Life Sciences, Liberty Testing Laboratory.
== Use == A common way to synthesize an NHS-activated acid is to mix NHS with the desired carboxylic acid and a small amount of an organic base in an anhydrous solvent. A coupling reagent such as dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is then added to form a highly reactive activated acid intermediate. NHS reacts to create a less labile activated acid. The group is usually written as SuO- or -OSu in chemical notation. Such an ester with acid and NHS, sometimes called succinate ester, is stable enough to be purified and stored at low temperatures in the absence of water and, as such, is commercially available. NHS esters are commonly used for protein modification (e.g. an NHS ester of fluorescein is commercially available, and can be added to a protein to obtain a fluorescently labeled protein in a straightforward reaction and purification step). NHS can be used with EDC to immobilize enzymes for biosensor applications.
Atherosclerosis is a pattern of the disease arteriosclerosis, characterized by the development of atheromatous plaques in the walls of arteries. This is a chronic inflammatory disease involving many different cell types and is driven by elevated blood levels of cholesterol, primarily LDL. These lesions lead to narrowing of the arteries. At the onset, there are usually no symptoms, but if they develop, symptoms generally begin around middle age. In severe cases, it can result in coronary artery disease, stroke, peripheral artery disease, or kidney disorders, depending on the body part(s) in which the affected arteries are located. The exact cause of atherosclerosis is unknown and is proposed to be multifactorial. Risk factors include abnormal cholesterol levels, elevated levels of inflammatory biomarkers, high blood pressure, diabetes, smoking (both active and passive smoking), obesity, genetic factors, family history, lifestyle habits, and an unhealthy diet. Plaque is made up of fat, cholesterol, immune cells, calcium, and other substances found in the blood. The narrowing of arteries limits the flow of oxygen-rich blood to parts of the body. Diagnosis is based upon a physical exam, electrocardiogram, and exercise stress test, among others, depending on the affected artery or arteries. Prevention guidelines include eating a healthy diet, exercising, not smoking, and maintaining a normal body weight.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.